Literature DB >> 1619410

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

D H Miller1, A J Thompson, S P Morrissey, D G MacManus, S G Moore, B E Kendall, I F Moseley, W I McDonald.   

Abstract

The integrity of the blood-brain barrier (BBB) in multiple sclerosis (MS) was monitored by serial gadolinium-(Gd)-DTPA enhanced MRI during and after the treatment of acute relapses with a three day course of high dose intravenous methylprednisolone (IVMP). During treatment there was a rapid reduction of BBB abnormalities in 96% of enhancing lesions. In spite of sustained clinical improvement, many lesions re-enhanced within a few days of stopping IVMP, and new lesions frequently appeared within one month. It is possible that the rapid, albeit transient, reversal of BBB abnormalities contributes to the accelerated recovery from relapses associated with IVMP treatment.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1619410      PMCID： PMC1014899          DOI： 10.1136/jnnp.55.6.450

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  24 in total

1.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.

Authors:  A G Kermode; A J Thompson; P Tofts; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; P Rudge; W I McDonald
Journal:  Brain       Date:  1990-10       Impact factor: 13.501

2.  Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts.

Authors:  P S Tofts; A G Kermode
Journal:  Magn Reson Med       Date:  1991-02       Impact factor: 4.668

3.  Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

Authors:  J O Harris; J A Frank; N Patronas; D E McFarlin; H F McFarland
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

4.  Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis.

Authors:  F Barkhof; O R Hommes; P Scheltens; J Valk
Journal:  Neurology       Date:  1991-08       Impact factor: 9.910

5.  Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.).

Authors:  H MILLER; D J NEWELL; A RIDLEY
Journal:  Lancet       Date:  1961-11-18       Impact factor: 79.321

6.  Intravenous methylprednisolone for multiple sclerosis in relapse.

Authors:  M P Barnes; D E Bateman; P G Cleland; D J Dick; T J Walls; P K Newman; M Saunders; P J Tilley
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

7.  Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

Authors:  A S Rose; J W Kuzma; J F Kurtzke; N S Namerow; W A Sibley; W W Tourtellotte
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

8.  Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone.

Authors:  D T Felson; J J Anderson
Journal:  Lancet       Date:  1987-04-18       Impact factor: 79.321

9.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis.

Authors:  D H Miller; P Rudge; G Johnson; B E Kendall; D G Macmanus; I F Moseley; D Barnes; W I McDonald
Journal:  Brain       Date:  1988-08       Impact factor: 13.501

10.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422
View more
  32 in total

Review 1.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

3.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

4.  Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5.

Authors:  Yoko Kashiwamura; Yasuteru Sano; Masaaki Abe; Fumitaka Shimizu; Hiroyo Haruki; Toshihiko Maeda; Motoharu Kawai; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-02-04       Impact factor: 3.996

5.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

6.  High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis.

Authors:  C Nos; M Comabella; M Tintoré; J Rio; A Codina; X Montalban; A Rovira
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

7.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Authors:  G Edan; D Miller; M Clanet; C Confavreux; O Lyon-Caen; C Lubetzki; B Brochet; I Berry; Y Rolland; J C Froment; E Cabanis; M T Iba-Zizen; J M Gandon; H M Lai; I Moseley; O Sabouraud
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

8.  Astrocytic tight junctions control inflammatory CNS lesion pathogenesis.

Authors:  Sam Horng; Anthony Therattil; Sarah Moyon; Alexandra Gordon; Karla Kim; Azeb Tadesse Argaw; Yuko Hara; John N Mariani; Setsu Sawai; Per Flodby; Edward D Crandall; Zea Borok; Michael V Sofroniew; Candice Chapouly; Gareth R John
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

9.  Reappraisal of Rasmussen's syndrome with special emphasis on treatment with high doses of steroids.

Authors:  D Chinchilla; O Dulac; O Robain; P Plouin; G Ponsot; J F Pinel; D Graber
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  Database for serial magnetic resonance imaging in multiple sclerosis.

Authors:  F Barkhof; A J Thompson; L Kappos; J J Nauta; T Yousri; I Berry; G Scotti; B Appel; P S Tofts; D H Miller
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.